Neumann HPH, Young WF, Eng C. Pheochromocytoma and paraganglioma. N. Engl J Med. 2019;381:552–65.
Article CAS PubMed Google Scholar
Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol. 2022;33:90–114.
Article CAS PubMed Google Scholar
Pereira BD, Luiz HV, Ferreira AG, Portugal J Genetics of pheochromocytoma and paraganglioma. In: Paraganglioma: a multidisciplinary approach. Codon Publications, 2019, pp 1–22.
Guha A, Musil Z, Vicha A, Zelinka T, Pacak K, Astl J, et al. A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas. Neoplasma. 2019;66:671–80.
Article CAS PubMed PubMed Central Google Scholar
Antonio K, Valdez MMN, Mercado-Asis L, Taïeb D, Pacak K. Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surg. 2020;9:105–23.
Article PubMed PubMed Central Google Scholar
Muth A, Crona J, Gimm O, Elmgren A, Filipsson K, Stenmark Askmalm M, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med. 2019;285:187–204.
Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, et al. Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention. JAMA Oncol. 2017;3:1204–12.
Article PubMed PubMed Central Google Scholar
Cleere EF, Martin-Grace J, Gendre A, Sherlock M, O’Neill JP. Contemporary management of paragangliomas of the head and neck. Laryngoscope Investig Otolaryngol. 2022;7:93–107.
Prasad SC, Paties CT, Pantalone MR, Mariani-Costantini R, Sanna M Carotid body and vagal paragangliomas: epidemiology, genetics, clinicopathological features, imaging, and surgical management. In: Paraganglioma: a multidisciplinary approach. Codon Publications, 2019, pp 81–98.
Prasad SC, Paties CT, Schiavi F, Esposito DL, Lotti LV, Mariani-Costantini R et al. Tympanojugular paragangliomas: surgical management and clinicopathological features. In: Paraganglioma: a multidisciplinary approach. Codon Publications, 2019, pp 99–123.
Prasad SC, Mimoune HA, D’Orazio F, Medina M, Bacciu A, Mariani-Costantini R, et al. The role of wait-and-scan and the efficacy of radiotherapy in the treatment of temporal bone paragangliomas. Otol Neurotol. 2014;35:922–31.
Taïeb D, Kaliski A, Boedeker CC, Martucci V, Fojo T, Adler JR, et al. Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev. 2014;35:795.
Article PubMed PubMed Central Google Scholar
Lassen-Ramshad Y, Ozyar E, Alanyali S, Poortmans P, van Houtte P, Sohawon S, et al. Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study. Head Neck. 2019;41:1770–6.
Roll W, Müther M, Sporns PB, Zinnhardt B, Suero Molina E, Seifert R, et al. Somatostatin receptor-targeted radioligand therapy in head and neck paraganglioma. World Neurosurg. 2020;143:e391–e399.
Jha A, Taïeb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, et al. High-specific-activity-131I-MIBG versus 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2021;27:2989–95.
Article CAS PubMed PubMed Central Google Scholar
Plouin PF, Amar L, Dekkers OM, Fassnach M, Gimenez-Roqueplo AP, Lenders JWM, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174:G1–G10.
Article CAS PubMed Google Scholar
Parisien S, Salle L, Chbat J, Lacroix A, Perrotte P, Karakiewicz P, et al. Postoperative recurrences in patients operated for pheochromocytomas and paragangliomas: new data supporting lifelong surveillance. Cancers. 2022;14:2942.
Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I, et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021;23:1995–2019.
Article CAS PubMed PubMed Central Google Scholar
Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, et al. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev. 2022;43:199–239.
Richter S, Qiu B, Ghering M, Kunath C, Constantinescu G, Luths C, et al. Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocr Relat Cancer. 2022;29:213–24.
Article CAS PubMed PubMed Central Google Scholar
Itani M, Mhlanga J. Imaging of pheochromocytoma and paraganglioma. In: Paraganglioma: a multidisciplinary Approach. Codon Publications, 2019, pp 41–61.
Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38:1443.
Article CAS PubMed PubMed Central Google Scholar
De Jong WHA, Graham KS, Van Der Molen JC, Links TP, Morris MR, Ross HA, et al. Plasma free metanephrine measurement using automated online solid-phase extraction HPLC–tandem mass spectrometry. Clin Chem. 2007;53:1684–93.
Peitzsch M, Prejbisz A, Kroiß M, Beuschlein F, Arlt W, Januszewicz A, et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: Utility for diagnosis of dopamineproducing metastatic phaeochromocytoma. Ann Clin Biochem. 2013;50:147–55.
Article CAS PubMed Google Scholar
März J, Kurlbaum M, Roche-Lancaster O, Deutschbein T, Peitzsch M, Prehn C, et al. Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors. Front Endocrinol (Lausanne). 2021;12:722656.
Erlic Z, Kurlbaum M, Deutschbein T, Nölting S, Prejbisz A, Timmers H, et al. Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. Eur J Endocrinol. 2019;181:647–57.
Article CAS PubMed Google Scholar
Moat SJ, George RS, Carling RS. Use of dried blood spot specimens to monitor patients with inherited metabolic disorders. Int J Neonatal Screen. 2020;6:26.
Article PubMed PubMed Central Google Scholar
Walker V. Ammonia metabolism and hyperammonemic disorders. Adv Clin Chem. 2014;67:73–150.
Article CAS PubMed Google Scholar
He L, Cai X, Cheng S, Zhou H, Zhang Z, Ren J, et al. Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma. Oncol Lett. 2019;17:5030–8.
CAS PubMed PubMed Central Google Scholar
Guo Y, Xiao Z, Yang L, Gao Y, Zhu Q, Hu L, et al. Hypoxia-inducible factors in hepatocellular carcinoma. Oncol Rep. 2020;43:3–15.
Jung MK, Okekunle AP, Lee JE, Sung MK, Lim YJ. Role of branched-chain amino acid metabolism in tumor development and progression. J Cancer Prev. 2021;26:237–43.
Article PubMed PubMed Central Google Scholar
Wang T, Yao W, He Q, Shao Y, Zheng R, Huang F. L-leucine stimulates glutamate dehydrogenase activity and glutamate synthesis by regulating mTORC1/SIRT4 pathway in pig liver. Anim Nutr. 2018;4:329–38.
Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell. 2021;184:2256.
Vaidya A, Flores SK, Cheng Z-M, Nicolas M, Deng Y, Opotowsky AR, et al. EPAS1 mutations and paragangliomas in cyanotic congenital heart disease. N. Engl J Med. 2018;378:1259–61.
Article PubMed PubMed Central Google Scholar
Corbet C, Draoui N, Polet F, Pinto A, Drozak X, Riant O, et al. The SIRT1/HIF2α axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy. Cancer Res. 2014;74:5507–19.
Article CAS PubMed Google Scholar
Yoo HC, Yu YC, Sung Y, Han JM. Glutamine reliance in cell metabolism. Exp Mol Med. 2020;52:1496–516. 2020 529.
Article CAS PubMed PubMed Central Google Scholar
Lorendeau D, Rinaldi G, Boon R, Spincemaille P, Metzger K, Jäger C, et al. Dual loss of succinate dehydrogenase (SDH) and complex I activity is necessary to recapitulate the metabolic phenotype of SDH mutant tumors. Metab Eng. 2017;43:187–97.
Article CAS PubMed Google Scholar
Fendt SM, Bell EL, Keibler MA, Olenchock BA, Mayers JR, Wasylenko TM, et al. Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells. Nat Commun. 2013;4:1–11.
Sarkadi B, Meszaros K, Krencz I, Canu L, Krokker L, Zakarias S, et al. Glutaminases as a novel target for sdhb-associated pheochromocytomas/paragangliomas. Cancers. 2020;12:599.
Article CAS PubMed PubMed Central Google Scholar
Blackburn PR, Hickey RD, Nace RA, Giama NH, Kraft DL, Bordner AJ, et al. Silent tyrosinemia type i without elevated tyrosine or succinylacetone associated with liver cirrhosis and hepatocellular carcinoma. Hum Mutat. 2016;37:1097–105.
留言 (0)